Your session is about to expire
← Back to Search
Reduced-Dose HPV Vaccine for Women with HIV (NOVA-HIV Trial)
NOVA-HIV Trial Summary
This trial will assess whether two doses of HPV vaccine are as effective as three doses in women living with HIV.
NOVA-HIV Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.NOVA-HIV Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have received an HPV vaccine in the past.I am unable to understand and agree to the study details on my own.I am not pregnant and willing to prevent pregnancy during the study.I have a cervix.
- Group 1: Routine schedule
- Group 2: Extended schedule
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Can people of all ages participate in this research?
"The age limit for participants in this trial is 45 years old. As long as individuals are over the age of 18, they may be eligible to enroll."
Would I be able to join this experiment?
"This experiment is looking for 450 people who have HIV and are between 18-45 years old. The most relevant criteria for participants are: a cervix, and being infected with the HIV virus."
Can new patients still join this clinical trial?
"Data from clinicaltrials.gov reveals that this particular trial is not presently looking for new patients to enroll. The trial was originally announced on September 1st, 2022 and updated last on August 8th, 2022. Even though this study isn't currently recruiting, there are 751 other trials which are still open for enrollment."
Has the Nonavalent HPV vaccine received its seal of approval from the FDA?
"The Nonavalent HPV vaccine is classified as a 3 in terms of safety. This means that while there is still some testing to be done in regards to its efficacy, the data collected thus far supports its use and multiple rounds have provided evidence for its safety."
Share this study with friends
Copy Link
Messenger